IRB #

STUDY00016393

Title

A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations

Principal Investigator

Jeremy Cetnar

Study Purpose

The purpose of this study is to study the effects, good and bad, of the study drug INCB054828 on participants and their urothelial carcinoma.

Medical Condition(s)

Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations

Eligibility Criteria

≥18 years old with metastatic or surgically unresectable urothelial carcinoma. Further labs, scans, and review of medical history will be done to confirm eligibility.

Age Range

18 - 120

Healthy Volunteers Needed

No

Duration of Participation

For as long as the participant is seeing benefit from the study drug

Minors Included

No

Contact

Knight Cancer Institute Clinical Trials
trials@ohsu.edu
503 494-1080

Sponsor

Incyte Corporation

Recruitment End

11/29/2017

Compensation Provided

No


Go Back